Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tisagenleucel

- PMLiVE

Sandoz granted positive CHMP opinion for multiple sclerosis biosimilar

The neurological disease affects approximately 2.8 million people worldwide

- PMLiVE

Novartis acquires DTx Pharma in deal worth up to $1bn

The agreement gives Novartis access to three preclinical neuroscience programmes

- PMLiVE

Novartis to sell eye-care products to Bausch + Lomb in deal worth up to $2.5bn

The transaction includes the Swiss drugmaker’s anti-inflammatory eye drop Xiidra

- PMLiVE

Novartis to acquire Chinook Therapeutics for approximately $3.5bn

The deal marks a notable expansion to the Swiss drugmaker's kidney disease pipeline

- PMLiVE

Novartis receives EC approval for Cosentyx in hidradenitis suppurativa

There are around 200,000 people in Europe living with moderate to severe stages of HS

- PMLiVE

Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment

Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...

Avalere Health

EU flag

EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug

The EU regulator concluded that the benefits of Adakveo did not outweigh its risks

- PMLiVE

Novartis’ Cosentyx recommended by CHMP for hidradenitis suppurativa

An estimated one in 100 people globally are affected by the inflammatory skin disease

- PMLiVE

Novartis announces positive long-term data for relapsing MS treatment Kesimpta

Approximately 85% of MS patients are initially diagnosed with relapsing forms of the disease

- PMLiVE

The challenges of reimbursement and innovative pricing for cell and gene therapies

Our policy and market access experts at Avalere, part of Fishawack Health, share insights on the reimbursement challenges for cell and gene therapies and discuss the challenges and opportunities of...

Avalere Health

- PMLiVE

Paris Court of Appeal overturns Novartis and Roche’s €444m anti-competitiveness fine

It was questioned whether the companies had used their market power to boost sales of their eye disease drug

- PMLiVE

Novartis’ Cosentyx shows continued improvement in hidradenitis suppurativa patients

An estimated one in 100 people globally are affected by the inflammatory skin disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links